New Treatment for Recurrent Meningioma: LUMEN-1 Clinical Trial

The European Organisation for Research and Treatment of Cancer (EORTC) is excited to announce the launch of the EORTC-2334-BTG LUMEN-1 clinical trial, a groundbreaking study aimed at finding potential new treatment options for patients with recurrent Meningioma. Meningioma is a type of brain tumour that can return after surgery and radiotherapy, leaving patients with limited treatment options.

The LUMEN-1 trial will investigate the effectiveness of a new treatment called [177Lu]Lu-DOTATATE, which targets a specific receptor found in most meningiomas. This treatment has shown promising results in smaller studies and is now being tested in a larger, randomised trial involving 136 patients across 35 sites in 10 European countries. This is a phase II study, meaning that it is a study aiming to show the activity of this therapy in treating recurrent Meningioma.

Patients participating in the trial will be randomly assigned to receive either [177Lu]Lu-DOTATATE or the current standard of care. The primary goal of the study is to determine whether [177Lu]Lu-DOTATATE can improve progression-free survival, allowing patients to live longer without their disease worsening. Secondary goals include assessing overall survival, safety, quality of life, and neurological function.

The trial also includes a comprehensive research program to explore various aspects of the treatment, such as dosimetry, imaging, and tissue analysis. The study is expected to be completed by 2029, with the hope of guiding the way forward to potential new, effective treatment options for patients with recurrent meningioma.

For more information about the LUMEN-1 trial, read here.